Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: Preliminary results from a randomized phase II clinical trial from Germany

Cancer Investigation

Volumn 19, Issue 2, 2001, Pages 107-113

  Bennett, C L ^a   Lane, D ^a   Stinson, T ^a   Glatzel, M ^a   Buntzel, J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CARBOPLATIN;

ADULT; ADVANCED CANCER; ARTICLE; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; COST BENEFIT ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEMALE; GERMANY; HEAD CANCER; HOSPITALIZATION; HUMAN; MALE; MUCOSA INFLAMMATION; NECK CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; XEROSTOMIA;

AMIFOSTINE; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; COSTS AND COST ANALYSIS; FEMALE; GERMANY; HEAD AND NECK NEOPLASMS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SALIVARY GLAND NEOPLASMS; TREATMENT OUTCOME;

EID: 0035082036     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-100000145     Document Type: Article

References (16)

1. Cancer statistics 1998
2. An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer
3. Chemoradiotherapy for head and neck cancer
4. Head and neck cancer
5. Concurrent radiation therapy and chemotherapy for locally advanced unresectable squamous cell head and neck cancer: An Eastern Cooperative Oncology Group Pilot Study
6. Phase I study of concomitant chemoradiotherapy with paclitaxel, fuorouracil, and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis cancer of the head and neck
7. Selective cytoprotection with amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy
8. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized controlled trial in patients with advanced ovarian cancer
9. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction
10. Amifostine and radiation therapy: Past, present, and future
11. Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies
12. Cost-utility assessment of amifostine in first-line therapy for ovarian cancer
13. Salivary gland protection by amifostine in high dose radio-iodine treatment: Results of a double-blind randomized controlled study
14. Germany's health care system
15. Granulocyte macrophage colony stimulating factor as adjunct thereapy in relapsed lymphoid malignancies: Implications for economic analyses alongside phase III clinical trials
16. Economic analysis alongside phase III clinical trials in cancer